Navigation Links
BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/7/2009

NOVATO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14th, 2009 at 11:00 a.m. PT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contacts:

     Investors                               Media
     Eugenia Shen                            Susan Berg
     BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
     (415) 506-6570                          (415) 506-6594

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
11. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... The ... in Tyler, has announced the latest beneficiary of their thriving community involvement program. ... organization dedicated to fulfilling the dreams of terminally ill patients. Donations to this ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Today, ... USA Wrestling announced a new agreement as part of a long-term extension ... December 2024 and includes the airing of some of the sport’s premier events exclusively ...
(Date:1/16/2017)... ... 17, 2017 , ... Recently, patients and staff from A Forever Recovery, a ... organizations in support of the annual Binder Park Zoo Halloween celebration known as the ... costumes of all designs coming out to enjoy games, face painting, and lots and ...
(Date:1/16/2017)... Village, IL (PRWEB) , ... January 16, 2017 ... ... personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at ... Convention Center in Las Vegas, Booth #2809. The SHOT Show is the shooting, ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... office , Antoine Dental Center, is currently offering complimentary consultations and financing for ... their teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017  Verathon ® Inc., a leading ... launch of new GlideScope ® Spectrum TM Single-Use video ... Control TM and Ambient Light Reduction TM technology, which ... ... Introducing another ...
(Date:1/16/2017)... ROCKVILLE, Md. , Jan. 16, 2017 /PRNewswire/ ... tomography (CT) systems market is valued at $4.9 ... applications for CT, coupled with an aging population ... incidence of chronic disease, is propelling the market ... report, Computed Tomography Markets , focuses on ...
(Date:1/16/2017)... 16, 2017 The ... Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), ... Surface Coatings & Paints), Region - Global ... market was valued at USD 4.51 Billion ... USD 6.41 Billion by 2021, at a ...
Breaking Medicine Technology: